Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 878-885

  Lin, Ting ^a   Ding, Yan Qing ^a   Li, Jian Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological characteristics; Diagnosis; Gastric adenocarcinoma; Immunohistochemistry; Nanog; Prognosis

Indexed keywords

TRANSCRIPTION FACTOR NANOG; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SIGNET RING CARCINOMA; STOMACH; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, SIGNET RING CELL; FEMALE; FOLLOW-UP STUDIES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864116184     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9860-9     Document Type: Article

References (34)

1. Echem R. Gastric cancer is a major cause of cancer death. Niger J Med. 2003;12:175-6.
2. Gruvberger SK, Ringner M, Eden P, Borg A, Ferno M, et al. Expression profiling to predict outcome in breast cancer: the influence of sample selection. Breast Cancer Res. 2003;5:23-6.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
4. Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA. Microarrays in breast cancer research and clinical practice-the future lies ahead. Endocr Relat Cancer. 2006;13:1017-31.
5. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006; 12:2979-90.
6. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947-56.
7. Chambers I, Colby D, Robertson M, Nichols J, Lee S, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113:643-55.
8. Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstrom P, et al. Exploring the two-gene ratio in breast cancer- independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008;107:225-34.
9. Linderholm BK, Gruvberger-Saal S, Ferno M, Bendahl PO, Malmstrom P. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast. 2008;17:484-91.
10. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez- Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007;13:823-32.
11. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007;31:836-45.
12. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007;67:4807-15.
13. Freberg CT, Dahl JA, Timoskainen S, Collas P. Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell. 2007;18: 1543-53.
14. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert- De Meyts E. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007;6:12.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-8.
16. Meng HM, Zheng P, Wang XY, Liu C, Sui HM, et al. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9:295-302.
17. Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer. 2005;104:2092-8.
18. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113:631-42.
19. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313-7.
20. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
21. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-6.
22. Pan G, Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 2007;17:42-9.
23. Pereira L, Yi F, Merrill BJ. Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol. 2006;26:7479-91.
24. Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, et al. Maintenance of embryonic stem cell pluripotency by Nanogmediated reversal of mesoderm specification. Nat Clin Pract Cardiovasc Med. 2006;3:114-22.
25. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 2005;104: 2255-65.
26. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009;27:993-1005.
27. Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell. 2008;3:196-206.
28. Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005;360:1-19.
29. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, et al. Inhibitory effect of a TGF beta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer. 2010;102:844-51.
30. Wang Z, Xu H, Wang S, Chen J. Relationship between new TNM classification and the prognosis and biological behavior of gastric cancer. Zhonghua Wai Ke Za Zhi. 2000;38:493-5.
31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
32. Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2:113-25.
33. Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer. 2008; 8:108.
34. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008; 14:4085-95.